October 18, 2017

Biocept Launches Pathology Partnership Initiative Expanding Access of Proprietary Liquid Biopsy Testing to Community Pathologists and Hospitals

First and only platform that enables local pathologists to obtain molecular biomarker information from a simple blood sample using cutting-edge circulating tumor cell (CTC) technology

SAN DIEGO, Oct. 18, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid testing designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces the launch of its molecular pathology partnership initiative, the aim of which is to incorporate community pathologists into the review of biomarkers found in liquid biopsy for patients diagnosed with cancer. Patient specimens will continue to be sent to Biocept for processing in its CLIA-certified, CAP-accredited laboratory.

"Having pathologists involved in the interpretation of liquid biopsy is important, as community physicians and hospitals want to take advantage of leading-edge medical solutions by providing the best patient care in their local health system," said Michael Terry, Senior Vice President, Commercial Operations at Biocept. "Combining liquid biopsy and the expertise of the local pathologist can provide better overall continuity of care when it comes to cancer diagnosis and treatment as they are the one of the first to know when a patient could benefit from a liquid biopsy. Our initial roll-out of this program showed strong acceptance by pathologists and clinicians, and we are now beginning to offer this program to additional cancer treatment centers around the country."

"We believe that local pathologists will value Biocept's ability to provide them with access to proprietary liquid biopsy technology, and we are looking forward to expanding and building new relationships in hospitals around the country with this program," said Biocept's President and Chief Executive Officer Michael Nall. "We continue to execute on expanding our physician services and our menu of non-invasive biomarker tests, in addition to our objective to increase the number of cancer indications addressed by our platform, making Biocept the go-to choice in liquid biopsy."

Biocept's Target Selector™ liquid biopsy tests are performed in its CLIA-certified, CAP-accredited laboratory located in San Diego, California. To order a liquid biopsy test or participate in the Pathology Partnership program, please contact Customer Service at **888-332-7729** or customerservice@biocept.com.

About Biocept
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company leverages its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news

release are not strictly historical, including, without limitation, statements as to our ability to identify specific clinical conditions or improve the outcomes of cancer patients, the utility and effectiveness of our intellectual property protections, the financial impact of new contracts, and our ability to increase the number of products or services provided or the value of the Company, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this news release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC at www.sec.gov

Investor Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100

Media Contact:
Trevelino/Keller
Colleen Murphy
cmurphy@trevelinokeller.com
404-214-0722, Ext. 109

View original content with multimedia:http://www.prnewswire.com/news-releases/biocept-launches-pathology-partnership-initiative-expanding-access-of-proprietary-liquid-biopsy-testing-to-community-pathologists-and-hospitals-300538625.html

SOURCE Biocept, Inc.